MX341014B - Anticuerpo anti-cmet novedoso. - Google Patents
Anticuerpo anti-cmet novedoso.Info
- Publication number
- MX341014B MX341014B MX2015000383A MX2015000383A MX341014B MX 341014 B MX341014 B MX 341014B MX 2015000383 A MX2015000383 A MX 2015000383A MX 2015000383 A MX2015000383 A MX 2015000383A MX 341014 B MX341014 B MX 341014B
- Authority
- MX
- Mexico
- Prior art keywords
- antibody
- receptor
- met
- cmet antibody
- specifically
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/53—Hinge
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
Abstract
La invención se refiere a un anticuerpo monoclonal, o su fragmento o derivado funcional divalente, capaz de inhibir la dimerización de c-Met, comprendiendo dicho anticuerpo una cadena pesada que comprende CDR-H1, CDR-H2 y CDR-H3 con respectivamente las secuencias de aminoácidos SEC ID Nos. 1, 2 y 3; y una cadena ligera que comprende CDR-L1, CDR-L2 y CDR-L3 con respectivamente las secuencias de aminoácidos SEC ID Nos. 5,6 y 7, el anticuerpo además se caracteriza porque también comprende una región bisagra que comprende la secuencia de aminoácidos seleccionada del grupo que consiste de SEC ID NO. 22 y 28 y SEC ID Nos. 58 a 72.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/IB2008/055663 WO2010064089A1 (en) | 2008-12-02 | 2008-12-02 | Novel anti-cmet antibody |
| US18450209P | 2009-06-05 | 2009-06-05 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX341014B true MX341014B (es) | 2016-08-03 |
Family
ID=41693124
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2011005677A MX2011005677A (es) | 2008-12-02 | 2009-12-02 | Anticuerpo anti-cmet novedoso. |
| MX2015000383A MX341014B (es) | 2008-12-02 | 2011-05-30 | Anticuerpo anti-cmet novedoso. |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2011005677A MX2011005677A (es) | 2008-12-02 | 2009-12-02 | Anticuerpo anti-cmet novedoso. |
Country Status (39)
| Country | Link |
|---|---|
| US (4) | US8741290B2 (es) |
| EP (4) | EP3135691B1 (es) |
| JP (3) | JP5863458B2 (es) |
| KR (1) | KR101838299B1 (es) |
| CN (2) | CN103351438B (es) |
| AR (1) | AR074439A1 (es) |
| AU (3) | AU2009328318C1 (es) |
| BR (2) | BRPI0923231B8 (es) |
| CA (1) | CA2743433C (es) |
| CL (2) | CL2011001296A1 (es) |
| CO (1) | CO6382139A2 (es) |
| CR (1) | CR20110324A (es) |
| CY (2) | CY1119172T1 (es) |
| DK (2) | DK2370468T3 (es) |
| EC (1) | ECSP11011127A (es) |
| ES (3) | ES2827277T3 (es) |
| GE (2) | GEP20146207B (es) |
| HK (2) | HK1190414A1 (es) |
| HR (2) | HRP20171011T8 (es) |
| HU (3) | HUE040553T2 (es) |
| IL (2) | IL213273A0 (es) |
| LT (2) | LT2370468T (es) |
| MA (1) | MA32892B1 (es) |
| MX (2) | MX2011005677A (es) |
| MY (2) | MY192567A (es) |
| NZ (1) | NZ593853A (es) |
| PE (1) | PE20120343A1 (es) |
| PH (1) | PH12015501515A1 (es) |
| PL (3) | PL3431502T3 (es) |
| PT (3) | PT2370468T (es) |
| RS (2) | RS58018B1 (es) |
| RU (2) | RU2015127471A (es) |
| SA (2) | SA112331005B1 (es) |
| SG (2) | SG187518A1 (es) |
| SI (3) | SI3431502T1 (es) |
| TN (1) | TN2011000216A1 (es) |
| TW (2) | TWI523866B (es) |
| WO (1) | WO2010069765A1 (es) |
| ZA (1) | ZA201105164B (es) |
Families Citing this family (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2014681A1 (en) | 2007-07-12 | 2009-01-14 | Pierre Fabre Medicament | Novel antibodies inhibiting c-met dimerization, and uses thereof |
| US8545839B2 (en) * | 2008-12-02 | 2013-10-01 | Pierre Fabre Medicament | Anti-c-Met antibody |
| EP2287197A1 (en) * | 2009-08-21 | 2011-02-23 | Pierre Fabre Medicament | Anti-cMET antibody and its use for the detection and the diagnosis of cancer |
| KR102059663B1 (ko) | 2010-03-10 | 2019-12-26 | 젠맵 에이/에스 | Ｃ―ｍｅｔ에 대한 모노클로날 항체 |
| WO2012030842A2 (en) | 2010-09-03 | 2012-03-08 | Academia Sinica | Anti-c-met antibody and methods of use thereof |
| EP3165538A1 (en) * | 2010-11-03 | 2017-05-10 | Argen-X Nv | Anti c-met antibodies |
| EP2710042A2 (en) | 2011-05-16 | 2014-03-26 | Fabion Pharmaceuticals, Inc. | Multi-specific fab fusion proteins and methods of use |
| KR20130036993A (ko) * | 2011-10-05 | 2013-04-15 | 삼성전자주식회사 | ｃ-Ｍｅｔ의 ＳＥＭＡ 도메인 내의 에피토프에 특이적으로 결합하는 항체 |
| KR101865223B1 (ko) | 2011-10-05 | 2018-06-08 | 삼성전자주식회사 | 항 ｃ-Ｍｅｔ 인간화 항체 및 그의 용도 |
| EP2773660A2 (en) | 2011-11-03 | 2014-09-10 | Argen-X B.V. | Chimeric human-camel antigens and their use |
| KR101463098B1 (ko) | 2011-11-28 | 2014-11-27 | 한국생명공학연구원 | ｃ-Ｍｅｔ에 대한 인간항체에 약물이 접합된 약물 복합체 및 이의 용도 |
| KR101910601B1 (ko) | 2011-12-22 | 2018-10-23 | 삼성전자주식회사 | 면역원성이 제거된 항 ｃ-Ｍｅｔ 인간화 항체 및 그의 용도 |
| CA2877573A1 (en) * | 2012-06-21 | 2013-12-27 | Sorrento Therapeutics, Inc. | Antigen binding proteins that bind c-met |
| US9931400B2 (en) | 2012-09-12 | 2018-04-03 | Samsung Electronics Co., Ltd. | Method of combination therapy for prevention or treatment of c-Met or angiogenesis factor induced diseases |
| ES2530968T3 (es) | 2012-10-12 | 2015-03-09 | Spirogen Sarl | Pirrolobenzodiazepinas y conjugados de las mismas |
| CN105209077B (zh) | 2013-03-13 | 2019-06-11 | 麦迪穆有限责任公司 | 吡咯并苯并二氮杂卓以及其结合物 |
| KR102049990B1 (ko) * | 2013-03-28 | 2019-12-03 | 삼성전자주식회사 | c-Met 항체 및 VEGF 결합 단편이 연결된 융합 단백질 |
| EP2992019B1 (en) | 2013-04-30 | 2019-03-06 | Agency For Science, Technology And Research | Mab 2 anti-met antibody |
| US9567641B2 (en) * | 2013-07-03 | 2017-02-14 | Samsung Electronics Co., Ltd. | Combination therapy for the treatment of cancer using an anti-C-met antibody |
| US9717715B2 (en) | 2013-11-15 | 2017-08-01 | Samsung Electronics Co., Ltd. | Method of combination therapy using an anti-C-Met antibody |
| ES2729797T3 (es) * | 2013-12-20 | 2019-11-06 | Dev Ct Biotechnology | Anticuerpos específicos de la alfa-enolasa y métodos de uso en terapias contra el cáncer |
| CN106687141A (zh) | 2014-09-10 | 2017-05-17 | 麦迪穆有限责任公司 | 吡咯并苯并二氮杂卓及其缀合物 |
| CN113150147A (zh) | 2015-03-16 | 2021-07-23 | 塞尔德克斯医疗公司 | 抗-met抗体及其使用方法 |
| US10927177B2 (en) | 2016-02-05 | 2021-02-23 | Helixmith Co., Ltd | Methods of treatment using anti-c-met antibodies |
| US10870701B2 (en) | 2016-03-15 | 2020-12-22 | Generon (Shanghai) Corporation Ltd. | Multispecific fab fusion proteins and use thereof |
| SG10201914095SA (en) | 2016-05-17 | 2020-03-30 | Abbvie Biotherapeutics Inc | ANTI-cMet ANTIBODY DRUG CONJUGATES AND METHODS FOR THEIR USE |
| US10457726B2 (en) | 2016-06-30 | 2019-10-29 | University Of Connecticut | Antibody and antigen-binding fragment compositions targeting cell surface antigens in tumors and methods of use thereof |
| JP2019534882A (ja) | 2016-10-11 | 2019-12-05 | メドイミューン・リミテッドＭｅｄＩｍｍｕｎｅ Ｌｉｍｉｔｅｄ | 免疫介在性療法薬を有する抗体−薬物コンジュゲート |
| WO2018088933A1 (en) * | 2016-11-14 | 2018-05-17 | Limited Liability Company "Panacela Labs" | Anti-tumor effects of a viral vector encoding a toll-like receptor and a toll-like receptor agonist |
| TWI782930B (zh) | 2016-11-16 | 2022-11-11 | 美商再生元醫藥公司 | 抗ｍｅｔ抗體，結合ｍｅｔ之雙特異性抗原結合分子及其使用方法 |
| US20180230218A1 (en) * | 2017-01-04 | 2018-08-16 | Immunogen, Inc. | Met antibodies and immunoconjugates and uses thereof |
| CN109771642B (zh) | 2017-11-13 | 2022-09-20 | 同济大学苏州研究院 | c-MET激动型抗体及其用途 |
| GB201803892D0 (en) | 2018-03-12 | 2018-04-25 | Ultrahuman Six Ltd | C-met binding agents |
| EP3796942A1 (en) | 2018-05-23 | 2021-03-31 | ADC Therapeutics SA | Molecular adjuvant |
| JP7482363B2 (ja) * | 2018-08-08 | 2024-05-14 | ドラゴンフライ セラピューティクス， インコーポレイテッド | Ｎｋｇ２ｄ、ｃｄ１６及び腫瘍関連抗原に結合するタンパク質 |
| CN109541221B (zh) * | 2018-10-24 | 2022-03-22 | 益善生物技术股份有限公司 | 一种c-Met特异性抗体、组合物及试剂盒 |
| KR102353568B1 (ko) * | 2018-11-14 | 2022-01-20 | 주식회사 헬릭스미스 | 안정성이 향상된 항 c-Met 항체 또는 그의 항원 결합 단편 |
| CN114340684A (zh) | 2019-09-16 | 2022-04-12 | 瑞泽恩制药公司 | 用于免疫pet成像的放射性标记的met结合蛋白 |
| US20230372528A1 (en) | 2020-10-16 | 2023-11-23 | University Of Georgia Research Foundation, Inc. | Glycoconjugates |
| GB202102396D0 (en) | 2021-02-19 | 2021-04-07 | Adc Therapeutics Sa | Molecular adjuvant |
| KR20230166099A (ko) * | 2021-04-08 | 2023-12-06 | 비온디스 비.브이. | 항-c-met 항체 및 항체-약물 접합체 |
| TW202304929A (zh) | 2021-04-29 | 2023-02-01 | 美商艾伯維有限公司 | 抗c-Met抗體藥物結合物 |
| US20230285394A1 (en) | 2022-03-11 | 2023-09-14 | Abbvie Biotherapeutics Inc. | Methods of treatment of non-small-cell lung carcinoma using telisotuzummab vedotin and osimertinib |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4424200A (en) | 1979-05-14 | 1984-01-03 | Nuc Med Inc. | Method for radiolabeling proteins with technetium-99m |
| US4479930A (en) | 1982-07-26 | 1984-10-30 | Trustees Of The University Of Massachusetts | Amines coupled wth dicyclic dianhydrides capable of being radiolabeled product |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4831175A (en) | 1986-09-05 | 1989-05-16 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Backbone polysubstituted chelates for forming a metal chelate-protein conjugate |
| IL162181A (en) | 1988-12-28 | 2006-04-10 | Pdl Biopharma Inc | A method of producing humanized immunoglubulin, and polynucleotides encoding the same |
| US5530101A (en) * | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| GB8924581D0 (en) | 1989-11-01 | 1989-12-20 | Pa Consulting Services | Bleaching of hair |
| GB9014932D0 (en) | 1990-07-05 | 1990-08-22 | Celltech Ltd | Recombinant dna product and method |
| WO1994004679A1 (en) * | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Method for making humanized antibodies |
| JPH05244982A (ja) | 1991-12-06 | 1993-09-24 | Sumitomo Chem Co Ltd | 擬人化ｂ−ｂ１０ |
| US5639641A (en) | 1992-09-09 | 1997-06-17 | Immunogen Inc. | Resurfacing of rodent antibodies |
| US5686292A (en) * | 1995-06-02 | 1997-11-11 | Genentech, Inc. | Hepatocyte growth factor receptor antagonist antibodies and uses thereof |
| KR20030068205A (ko) * | 2001-01-09 | 2003-08-19 | 메르크 파텐트 게엠베하 | 수용체 타이로신 키나아제 저해제 및 혈관형성 저해제를사용하는 병용 요법 |
| EP1592713A2 (en) * | 2003-02-13 | 2005-11-09 | Pharmacia Corporation | Antibodies to c-met for the treatment of cancers |
| HN2004000285A (es) | 2003-08-04 | 2006-04-27 | Pfizer Prod Inc | ANTICUERPOS DIRIGIDOS A c-MET |
| CA2548282A1 (en) * | 2003-12-11 | 2005-06-30 | Genentech, Inc. | Methods and compositions for inhibiting c-met dimerization and activation |
| PL1773885T3 (pl) | 2004-08-05 | 2010-09-30 | Genentech Inc | Humanizowani antagoniści anty c-met |
| EP1874816A4 (en) * | 2005-04-26 | 2010-08-25 | Medimmune Inc | MODULATION OF THE ANTIBODY EFFECTOR FUNCTION BY "HINGE" DOMENGINE ENGINEERING |
| EP1915398B1 (en) * | 2005-07-18 | 2016-04-20 | Amgen Inc. | Human anti-b7rp1 neutralizing antibodies |
| EP1913027B1 (en) * | 2005-07-28 | 2015-03-04 | Novartis AG | M-csf specific monoclonal antibody and uses thereof |
| RU2008142833A (ru) | 2006-03-30 | 2010-05-10 | Новартис АГ (CH) | КОМПОЗИЦИИ И СПОСОБЫ ПРИМЕНЕНИЯ АНТИТЕЛ К c-Met |
| EP2014681A1 (en) * | 2007-07-12 | 2009-01-14 | Pierre Fabre Medicament | Novel antibodies inhibiting c-met dimerization, and uses thereof |
| US8545839B2 (en) | 2008-12-02 | 2013-10-01 | Pierre Fabre Medicament | Anti-c-Met antibody |
-
2009
- 2009-12-01 AR ARP090104624A patent/AR074439A1/es active IP Right Grant
- 2009-12-02 JP JP2011539008A patent/JP5863458B2/ja active Active
- 2009-12-02 PL PL18188726T patent/PL3431502T3/pl unknown
- 2009-12-02 EP EP16192250.5A patent/EP3135691B1/en active Active
- 2009-12-02 ES ES18188726T patent/ES2827277T3/es active Active
- 2009-12-02 CN CN201310286587.2A patent/CN103351438B/zh active Active
- 2009-12-02 CA CA2743433A patent/CA2743433C/en active Active
- 2009-12-02 TW TW103130374A patent/TWI523866B/zh active
- 2009-12-02 GE GEAP200912919A patent/GEP20146207B/en unknown
- 2009-12-02 RS RS20181344A patent/RS58018B1/sr unknown
- 2009-12-02 AU AU2009328318A patent/AU2009328318C1/en active Active
- 2009-12-02 EP EP09771324.2A patent/EP2370468B1/en active Active
- 2009-12-02 PT PT97713242T patent/PT2370468T/pt unknown
- 2009-12-02 SI SI200932092T patent/SI3431502T1/sl unknown
- 2009-12-02 PL PL09771324T patent/PL2370468T3/pl unknown
- 2009-12-02 MY MYPI2020006937A patent/MY192567A/en unknown
- 2009-12-02 DK DK09771324.2T patent/DK2370468T3/en active
- 2009-12-02 KR KR1020117013758A patent/KR101838299B1/ko active IP Right Grant
- 2009-12-02 MX MX2011005677A patent/MX2011005677A/es active IP Right Grant
- 2009-12-02 DK DK16192250.5T patent/DK3135691T3/en active
- 2009-12-02 TW TW098141151A patent/TWI459964B/zh active
- 2009-12-02 PT PT16192250T patent/PT3135691T/pt unknown
- 2009-12-02 PT PT181887266T patent/PT3431502T/pt unknown
- 2009-12-02 GE GEAP200912279A patent/GEP20135930B/en unknown
- 2009-12-02 SG SG2013005772A patent/SG187518A1/en unknown
- 2009-12-02 HU HUE16192250A patent/HUE040553T2/hu unknown
- 2009-12-02 LT LTEP09771324.2T patent/LT2370468T/lt unknown
- 2009-12-02 RS RS20170671A patent/RS56204B1/sr unknown
- 2009-12-02 HU HUE18188726A patent/HUE051288T2/hu unknown
- 2009-12-02 EP EP20187010.2A patent/EP3757132A1/en active Pending
- 2009-12-02 RU RU2015127471A patent/RU2015127471A/ru not_active Application Discontinuation
- 2009-12-02 CN CN200980148150.4A patent/CN102227446B/zh active Active
- 2009-12-02 PE PE2011001117A patent/PE20120343A1/es active IP Right Grant
- 2009-12-02 BR BRPI0923231A patent/BRPI0923231B8/pt active IP Right Grant
- 2009-12-02 ES ES09771324.2T patent/ES2629855T3/es active Active
- 2009-12-02 PL PL16192250T patent/PL3135691T3/pl unknown
- 2009-12-02 WO PCT/EP2009/066201 patent/WO2010069765A1/en active Application Filing
- 2009-12-02 SG SG2011038817A patent/SG171851A1/en unknown
- 2009-12-02 MY MYPI2011002426A patent/MY185200A/en unknown
- 2009-12-02 RU RU2011124751/10A patent/RU2560257C2/ru active
- 2009-12-02 US US13/132,211 patent/US8741290B2/en active Active
- 2009-12-02 SI SI200931893T patent/SI3135691T1/sl unknown
- 2009-12-02 HU HUE09771324A patent/HUE035047T2/en unknown
- 2009-12-02 EP EP18188726.6A patent/EP3431502B1/en active Active
- 2009-12-02 NZ NZ593853A patent/NZ593853A/xx unknown
- 2009-12-02 ES ES16192250T patent/ES2697098T3/es active Active
- 2009-12-02 SI SI200931680T patent/SI2370468T1/sl unknown
- 2009-12-02 BR BR122019023930-4A patent/BR122019023930B1/pt active IP Right Grant
- 2009-12-02 LT LTEP16192250.5T patent/LT3135691T/lt unknown
- 2009-12-05 SA SA112331005A patent/SA112331005B1/ar unknown
- 2009-12-05 SA SA109300720A patent/SA109300720B1/ar unknown
-
2011
- 2011-05-03 TN TN2011000216A patent/TN2011000216A1/fr unknown
- 2011-05-30 MX MX2015000383A patent/MX341014B/es unknown
- 2011-05-31 IL IL213273A patent/IL213273A0/en active IP Right Grant
- 2011-06-01 CL CL2011001296A patent/CL2011001296A1/es unknown
- 2011-06-10 MA MA33933A patent/MA32892B1/fr unknown
- 2011-06-13 EC EC2011011127A patent/ECSP11011127A/es unknown
- 2011-06-13 CR CR20110324A patent/CR20110324A/es unknown
- 2011-06-14 CO CO11073992A patent/CO6382139A2/es active IP Right Grant
- 2011-07-13 ZA ZA2011/05164A patent/ZA201105164B/en unknown
-
2012
- 2012-03-23 HK HK14103516.3A patent/HK1190414A1/zh unknown
- 2012-03-23 HK HK12102920.7A patent/HK1162536A1/zh unknown
- 2012-09-14 US US13/619,920 patent/US8765128B2/en active Active
- 2012-09-14 US US13/619,730 patent/US8747850B2/en active Active
- 2012-09-14 US US13/619,910 patent/US8729249B2/en active Active
-
2014
- 2014-01-24 CL CL2014000181A patent/CL2014000181A1/es unknown
- 2014-03-13 IL IL231525A patent/IL231525B/en active IP Right Grant
-
2015
- 2015-07-03 PH PH12015501515A patent/PH12015501515A1/en unknown
- 2015-12-15 JP JP2015244007A patent/JP6074018B2/ja active Active
-
2016
- 2016-02-04 AU AU2016200725A patent/AU2016200725C1/en active Active
-
2017
- 2017-01-05 JP JP2017000641A patent/JP6309657B2/ja active Active
- 2017-06-09 AU AU2017203929A patent/AU2017203929B2/en active Active
- 2017-07-03 CY CY20171100707T patent/CY1119172T1/el unknown
- 2017-07-04 HR HRP20171011TT patent/HRP20171011T8/hr unknown
-
2018
- 2018-11-09 HR HRP20181868TT patent/HRP20181868T1/hr unknown
- 2018-11-09 CY CY181101191T patent/CY1121025T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12015501515A1 (en) | Anti-cmet antibody | |
| MY150136A (en) | Picolinamide derivatives as kinase inhibitors | |
| MX2009009304A (es) | Inhibidores de cinasa pim y metodos para su uso. | |
| TW201129378A (en) | Materials and methods for treating or preventing HER-3 associated diseases | |
| WO2012059857A3 (en) | Pan-her antibody composition | |
| MX2007015487A (es) | Moleculas que son capaces de inhibir la union entre el factor de crecimiento de nervios y el receptor trka como analgesicos con efecto prolongado. | |
| MX2010010317A (es) | Compuestos heterociclicos novedosos y usos de los mismos. | |
| MX2012002066A (es) | Compuestos heterociclicos y usos de los mismos. | |
| TN2012000558A1 (en) | Novel anti-cmet antibody | |
| UA109878C2 (uk) | Похідні ізохінолінону, фармацевтична композиція на їх основі (варіанти) та спосіб лікування захворювань (варіанти) | |
| WO2012032209A3 (es) | Uso de un agonista de trpm8 para la elaboración de un medicamento para el tratamiento de xeroftalmia, sequedad vaginal y síndrome de la boca seca y uso de un antagonista de trpm8 para la elaboración de un medicamento pra el tratamiento de la epífora. | |
| CL2009000873A1 (es) | Compuestos derivados de ciclohepta[b]piridina, antagonistas del receptor de cgrp; composicion farmaceutica; y uso para el tratamiento de la migrana.b | |
| CL2008001025A1 (es) | Compuestos derivados de pirimido[5,4-d]pirimidina-2,4,6,8-tetraona; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como trastorno metabolico, dislipidemia y cancer. | |
| MX2010009743A (es) | Uso de derivados de pirimidina para el tratamiento de las enfermedades dependientes de los receptores del factor de crecimiento epidermico (egfr) o de enfermedades que hayan adquirido resistencia a los agentes que se dirigen a los miembros de la fami | |
| WO2012001065A3 (en) | Use of alpha-adrenergic receptor agonist for preventing or treating skin tumor | |
| MX342947B (es) | Tratamiento de diabetes tipo 2. | |
| MX2009003039A (es) | Utilizacion de un anticuerpo anti-cd151 para el tratamiento del cancer. | |
| MX2014009277A (es) | Antagonistas alk1 y sus usos en el tratamiento de carcinoma de celula renal. | |
| MX2010008994A (es) | Combinacion que comprende paclitaxel para el tratamiento del cancer de ovario. | |
| EP2604276A4 (en) | USE OF ANTIBODIES TO NK1, NK2 AND / OR NK3 RECEPTORS IN CANCER THERAPY | |
| TN2011000428A1 (en) | Uses of nk receptor antagonists | |
| MX2012013527A (es) | Quinazolinas policíclicas, preparación de las mismas, y uso de las mismas. | |
| UA98472C2 (ru) | Применение агониста рецептора epo человека для лечения интолерантности к глюкозе | |
| UA94055C2 (en) | Substituted benzimidazoles and methods of preparation | |
| WO2012001064A3 (en) | Use of alpha-adrenergic receptor agonist for preventing or treating skin tumor |